{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-25-000130","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.452299+00:00","generated_at":"2026-05-17T18:24:36.399989+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M","bullets":["Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).","Recorlev net revenue $31.4M (+136%) driven by 122% increase in average patients on therapy.","Gvoke revenue $23.5M (+17%); Keveyis $11.5M (-13%) on reduced shipments.","Adjusted EBITDA improved to $12.5M vs -$0.4M in Q2 2024.","Raised FY 2025 revenue guidance to $280-290M from $260-275M; long-term target $750M by 2030."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-25-000130","json":"https://secwatch.observer/filing/0001867096-25-000130.json","markdown":"https://secwatch.observer/filing/0001867096-25-000130.md","text":"https://secwatch.observer/filing/0001867096-25-000130.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/0001867096-25-000130-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709625000130/xers-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:24:36.399989+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}